J&J Medical Connect
DARZALEX FASPRO®

(daratumumab and hyaluronidase-fihj)

This information is intended for US patients and caregivers to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended to promote the use of our products, nor to provide medical advice.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

Patient Medical Information

How is DARZALEX FASPRO Administered?

Last Updated: 09/16/2024

summary

Here is a passage from the DARZALEX FASPRO PATIENT INFORMATION which may be helpful in addressing your question:

How will I receive DARZALEX FASPRO?

  • DARZALEX FASPRO may be given alone or together with other medicines used to treat multiple myeloma.1
  • DARZALEX FASPRO will be given to you by your healthcare provider as an injection under the skin, in the stomach area (abdomen).1
  • DARZALEX FASPRO is injected over 3 to 5 minutes.1
  • Your healthcare provider will decide the time between doses as well as how many treatments you will receive.1
  • Your healthcare provider will give you medicines before each dose of DARZALEX FASPRO and after each dose of DARZALEX FASPRO to help reduce the risk of serious allergic reactions and other reactions due to release of certain substances by your body (systemic).1
  • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.1
  • The route of administration of DARZALEX FASPRO has been shown in the Figure: How is DARZALEX FASPRO Administered?

How is DARZALEX FASPRO Administered?1

Abbreviations: HCP, healthcare provider; no., number.
a3 to 5 minutes refers to the time it takes to administer DARZALEX FASPRO and does not represent the entire duration of clinic visit.

additional information

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest using it in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare team(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT INFORMATION for DARZALEX FASPRO.1

 

References

1 DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf.